Watch Ortoma AB Series B for free: we tell you when fair value or trend changes.
Data-driven stock valuation
Ortoma AB Series B (ORT-B) fair value: what the stock is really worth
As of Oct 20, 2026: fair value (intrinsic value) of Ortoma AB Series B stock SEK 1.84, price SEK 7.15, upside -74.3%, quality 38 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
OA
Thin data
Oct 3, 2026
Thin data
Oct 3, 2026
Ortoma AB Series B
ORT-B · STWeakest SetupStrongly overvalued and low quality.
Our calculation puts a fair price 74% below what the stock costs today.
Generates free cash flow
Mixed Growth (revenue YoY +31.6 %/yr in SEK)
Fair value kr 1.84 · Strongly overvalued (−74.3%)
Quality 38/100
Loss-making · -194.5% net margin (TTM)
Trails peers (0/9)
Narrow moat 12/100 · thin data
Thin data
⚠ Dilution
Watch Ortoma AB Series B for free: we tell you when fair value or trend changes.
Watch for free
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range kr 6.50 – kr 36.40 · fair‑value band kr 1.12 – kr 2.48 · the kr 7.15 price screens above the kr 1.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Ortoma AB Series B in your weekly email
Every Wednesday you see whether Ortoma AB Series B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Ortoma AB (publ) provides orthopedic surgical products in Sweden.
Show moreShow less
It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and post-operative follow-up; and OTS Guide, an intra-operative navigation tool guiding surgeons to place the implant in the pre-operatively planned position.
The company was incorporated in 2001 and is based in Gothenburg, Sweden.
Stock analysis
Ortoma AB Series B (ORT-B) currently trades at kr 7.15, while our model-based Fair Value estimate is kr 1.84, 74.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 2.16 per share, and 0 of the 7 models we run sit above the kr 7.15 price.
Bear case: the Asset-Based group reads lowest at kr 0.4900, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: kr 1.12 (bear) to kr 2.48 (bull), the price of kr 7.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ortoma AB Series B reported revenue of 64.6M SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −19.2M SEK in FY2025.
Key figures
Market cap 335M SEK (≈ $33.7M) Micro · P/S ratio 9.96 · EPS (TTM) kr −1.68 · Net margin −29.7% · Return on equity −37.3% · Return on assets (EBIT) −7.8% · Operating margin −204% · Revenue (TTM) 33.9M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −74%, ORT-B screens richer than that median.
Fair Value models
Bear kr 1.12
Fair Value kr 1.84
Bull kr 2.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF
kr 1.55
kr 2.16
kr 4.11
72
Growth DCF
kr 1.48
kr 2.47
kr 4.07
70
5Y Revenue Exit
kr 1.24
kr 1.78
kr 2.92
66
All 7 models by family
DCF Models
FCF DCF
kr 1.55
kr 2.16
kr 4.11
72
5Y Revenue Exit
kr 1.24
kr 1.78
kr 2.92
66
10Y Revenue Exit
kr 1.32
kr 2.28
kr 2.87
62
Multiples
EV/Revenue
kr 1.06
kr 1.31
kr 1.57
52
Asset-Based
NCAV (Graham)
kr 0.3300
kr 0.4900
kr 0.6200
52
Growth DCF
Growth DCF
kr 1.48
kr 2.47
kr 4.07
70
Rev-Margin DCF
kr 1.30
kr 1.97
kr 3.35
65
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
Overall quality
38/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
17
How much profit the company makes from its sales and capital
Quality Growth
40
Are margins and returns getting better?
Cashflow
32
Do the profits arrive as real cash?
Financial strength
86
Debt, balance sheet and risk of trouble
Investment
79
Does it invest with discipline instead of growing at any price?
Low Volatility
37
How calm the share price moves, does not count
Momentum
12
Price trend of the last 3 to 12 months, does not count
Near the 52-week high
1
Distance to the 52-week high, does not count
New shares
0
Buys back shares or issues new ones?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
49/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +37.5% a year for the price.
ORT-B screens overvalued: fair value 74% below the price. Compare with Abbott Laboratories, →
Compare Ortoma AB Series B with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 325 stocks
Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation Multiplesvs Medical Devices median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Valuation of the Sweden market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Stryker Corporation SYK | $282.60 | $310.86 | +10% | vs ORT-B |
| Boston Scientific Corporation BSX | $43.00 | $47.30 | +10% | vs ORT-B |
| DexCom, Inc DXCM | $85.98 | $94.58 | +10% | vs ORT-B |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥166.00 | ¥182.60 | +10% | vs ORT-B |
| GE HealthCare Technologies Inc GEHC | $65.74 | $70.37 | +7% | vs ORT-B |
| Edwards Lifesciences Corporation EW | $86.60 | $81.94 | −5% | vs ORT-B |
| Siemens Healthineers AG SHL | €41.45 | €35.19 | −15% | vs ORT-B |
| Abbott Laboratories, ABT | $102.61 | $74.79 | −27% | vs ORT-B |
| Medtronic plc MDT | $91.93 | $65.61 | −29% | vs ORT-B |
| Koninklijke Philips N.V PHIA | €22.18 | €15.23 | −31% | vs ORT-B |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Ortoma AB Series B (ORT-B) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 1.84 versus a price of kr 7.15, about −74% upside (overvalued).
What is the fair value of ORT-B?
Our model-based fair value for Ortoma AB Series B is kr 1.84 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 7.15.
What is the quality score of ORT-B?
Ortoma AB Series B has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ortoma AB Series B (ORT-B)?
Our model-based price target is the fair value of kr 1.84 (as of Oct 3, 2026) from 7 valuation models. Cautious scenario kr 1.12, optimistic scenario kr 2.48. It is a calculation from audited fundamentals, not an analyst target.
What is the Ortoma AB Series B stock forecast for 2026?
Our models put fair value at kr 1.84, about −74% upside versus a price of kr 7.15 (overvalued). Cautious scenario kr 1.12, optimistic scenario kr 2.48. The calculation is refreshed regularly with new filings.
What is the revenue of Ortoma AB Series B (ORT-B)?
Ortoma AB Series B reported trailing-twelve-month revenue of about 33.9M SEK (latest available figure, as of Oct 3, 2026).
What growth is priced into Ortoma AB Series B (ORT-B)?
For today's price to be fair in a discounted-cash-flow model, Ortoma AB Series B would have to grow free cash flow by +40.2 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew +30.2 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of ORT-B use?
Our models discount Ortoma AB Series B at 9.1 %: a base by market capitalisation (nano), damped by beta 0.84, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ortoma AB Series B that is +40.2 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Ortoma AB Series B (ORT-B) delivered so far?
Over the past 2 years revenue at Ortoma AB Series B grew +30.2 % a year. The price currently implies +40.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ortoma AB Series B (ORT-B) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Ortoma AB Series B (+40.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ortoma AB Series B (ORT-B)?
The free-cash-flow yield on the price is 0.88 %: that much free cash flow Ortoma AB Series B produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ortoma AB Series B (ORT-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ortoma AB Series B it is kr 1.84 per share (as of Oct 3, 2026), against a price of kr 7.15. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Ortoma AB Series B stock overvalued or undervalued in 2026?
As of Oct 3, 2026, ORT-B trades above its calculated fair value: price kr 7.15, fair value kr 1.84, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORT-B?
No. The price is what the market pays today (kr 7.15); the fair value is what the company's own numbers justify (kr 1.84). For Ortoma AB Series B the two are kr 5.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ortoma AB Series B worth?
The market values Ortoma AB Series B at about 335M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 7.15; our models calculate a fair value of kr 1.84 per share.
What do the bullish and bearish scenarios say about ORT-B?
Our models span a range for Ortoma AB Series B: cautious scenario kr 1.12, base kr 1.84, optimistic kr 2.48 per share (as of Oct 3, 2026, price kr 7.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ortoma AB Series B (ORT-B)?
Balance-sheet figures for Ortoma AB Series B (as of Oct 3, 2026): return on equity −37.3%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ORT-B from its 52-week high?
Ortoma AB Series B trades at kr 7.15, about 62% below its 52-week high of kr 19.00 and 3% above the low of kr 6.95 (as of Oct 20, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.84 is for.
Which stocks are comparable to Ortoma AB Series B?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ortoma AB Series B stock attractive at the current price?
The data as of Oct 3, 2026: price kr 7.15, calculated fair value kr 1.84 (−74%), Quality Score 38/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ORT-B calculated?
We run Ortoma AB Series B through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 1.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Ortoma AB Series B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ortoma AB Series B (ORT-B)?
The closing price on Oct 20, 2026 was kr 7.15. Our model-based fair value is kr 1.84, about −74% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ortoma AB Series B right now?
The price sits above even our optimistic bull case (kr 2.48). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 1.12 to kr 2.48) leaves room in how you read the outcome.
Key figures of Ortoma AB Series B
How large is the market capitalisation of Ortoma AB Series B (ORT-B)?
The market capitalisation of Ortoma AB Series B is 335M SEK (≈ $33.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ortoma AB Series B (ORT-B)?
The price-to-sales ratio of Ortoma AB Series B is 9.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ortoma AB Series B (ORT-B)?
Earnings per share at Ortoma AB Series B are kr −1.68. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ortoma AB Series B (ORT-B)?
The net margin of Ortoma AB Series B is −29.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ortoma AB Series B (ORT-B)?
The return on equity (ROE) of Ortoma AB Series B is −37.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ortoma AB Series B (ORT-B)?
On an EBIT basis the return on assets of Ortoma AB Series B is −7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ortoma AB Series B (ORT-B)?
The operating margin of Ortoma AB Series B is −204% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ortoma AB Series B (ORT-B)?
Revenue at Ortoma AB Series B is growing −45.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ortoma AB Series B (ORT-B)?
Earnings per share at Ortoma AB Series B are growing −79.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Ortoma AB Series B in the live analysis
One click puts Ortoma AB Series B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.